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Abstract
Bovine liver 5X-nucleotidase is a GPI-anchored protein whose Ser 523 attaches to GPI as the v-site. For GPI-modification,
pro-protein of the enzyme possesses a signal peptide at the C-terminus, comprising a hydrophilic spacer sequence of 8
amino acid residues and the following hydrophobic region of 17 amino acid residues. The C-terminal signal peptide is
replaced by GPI on a luminal leaflet of endoplasmic reticulum. To characterize the C-terminal signal peptide for GPI
modification, we constructed a series of deletion and elongation mutant genes, altering length of the hydrophilic spacer
sequence by site-directed mutagenesis. Systematic deletion and Ala insertion of the sequence showed that the sequence of
6–14 residues were compatible for GPI modification. For GPI transfer to the pro-protein, the optimum length of spacer
sequence would be 8, being consistent with natural selection. The spacer sequence may play a role for leading the v-residue
correctly to the active site of putative GPI transamidase. The elongation of the spacer is more permissible than deletion.
Nevertheless, the length of the spacer sequence may influence efficiency of GPI modification by its positive or negative
control. q 1997 Elsevier Science B.V.
Keywords: 5X-Nucleotidase; Glycosylphosphatidylinositol; Hydrophilic spacer sequence; Site directed mutagenesis; Post translational
modification; Glycosylphosphatidylinositol anchor
1. Introduction
 .Glycosylphosphatidylinositol GPI -anchored pro-
teins are widely distributed over eukaryotic cells
w x1,2 , and their presence in archaebacteria was re-
w xcently demonstrated 3 . Precursor polypeptides of the
Abbreviations: DAF, decay-accelerating factor; GPI, glyco-
sylphosphatidylinositol; PI-PLC, phosphatidylinositol-specific
phospholipase C
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 .GPI-anchored proteins prepro-protein have signal
peptides at its N- and C-termini. The N-terminal
signal peptide for secretion is removed from the
nascent polypeptide and the resulting pro-protein is
transferred into the luminal side of the endoplasmic
reticulum. The C-terminal signal peptide for GPI
modification ends by a short stretch of hydrophobic
region, and the pro-protein binds to the luminal mem-
brane by that region. However, the pro-protein is
modified immediately with GPI moiety by a putative
GPI transamidase. Systematic deletion of the C-
terminal hydrophobic region demonstrated the re-
0005-2736r97r$17.00 q 1997 Elsevier Science B.V. All rights reserved.
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Table 1
The amino acid sequences of the C-terminal signal peptides of the GPI-anchored protein precursors
Protein C-Terminal amino acid sequence
Spacer sequence Hydrophobic region
v vq1 vq2
 .p137 human GSRG A R G LMNGYRGPAMDSEED MMVTALHSLTLQTVVIHSLSSVLPGITLAIN
 .E48 human CCQE D L C NEKLHNAAPTRTA LAHSALSLGLALSLLAVILAPSL
 .CEA human ITVS A S G TSPGLSAGAT VGIMIGVLVGVALI
 .ThB mouse TDLC N E R LVSAAPGHA LLSSVTLGLATSLSLLTVMALCL
 .Thy-1 rat KLVK C G G ISLLVQNTS WLLLLLLSLSFLQATDFISL
 .Thy-1 human KLVK C E G ISLLAQNTS WLLLLLLSLSLLQATDFMSL
 .GAS1 yeast SSKK N A A TNVKANLAQ VVFTSIISLSIAAGVGFALV
 .Sca-2 mouse SSFC N F S AAGLGLRAS IPLLGLGLLLSLLALLQLSP
 .LY-6C antigen mouse EDLC N A A VPTGASTWT MAGVLLFSLSSVILQTLL
 .DAF human SGTT S G T TRLLSGHTC FTLTGLLGTLVTMGLLT
 .Dipeptidase pig NYGY S A A PSLHLPPGS LLASLVPLLLLSLP
VSG YNat 1.1 SHLP S G S SHGTKAIRS ILHVALLM
 .T. congolense
 .PHR1 C. albicans GSSS S S G VKATQQMS MVKLVSIITIVTAFVGGMSVVF
 .N-CAM chicken TVIP A T L GSPSTSSS FVSLLLSAVTLLLLC
 .Folate receptor-b human AMHV N A G EMLHGTGG LLLSLALMLQLWLLG
 .AP-P pig EPLS A R A APTTSLGS LMTVSALAILGWSV
 .GP2 rat NGTP R N T GFLLAWPT FFLPVFLAWLF
 .u-PAR human QYRS G A A PQPGPAH LSLTITLLMTARLWGGTLLWT
 .LFA-3 antigen human TCIP S S G HSRHRYA LIPIPLAVITTCIVLYMNVL
 .Glypican rat GQKT S A A TRPEPHY FFLLFLFTLVLAAARPRWR
 .CD59 human EQLE N G G TSLSEKT VLLLVTPFLAAAWSLHP
 .AChE Torpedo DGEL S S S GTSSSKG IIFYVLFSILYLIFY
 .Prion protein hamster DGRR S S A VLFSSPP VILLISFLIFLMVG
 .Brevican rat APSS G N S AEGSMPA FLLFLLLQLWDT
 .VSG ILTat 1.1 T. brucei NTTG S N S FVIHKAP LFLAFLLF
 .VSG TxTat 1 T. brucei NTTA S N S FVINKAP LLLGFLLF
 .VSG MIT 221 T. brucei TTGS S N S FVISKTP LWLAVLLF
 .RT6.2 rat NCLY S S A GARESC VSLFLVVLPSLLVQLLCLAEP
 .Melanotransferrin chicken QCSG A G N KLIQQH LLVITFVPFIILGQLQGLG
 .DIP human YGYS S G A SSLHRH FGLLLASLAPLVLCLSLL
X  .5 -Nucleotidase rat RIKF S A A SHYQGS FPLIILSFWAVILVLYQ
X  .5 -Nucleotidase human RIKF S T G SHCHGS FSLIFLSLWAVIFVLYQ
X  .5 -Nucleotidase bovine RIQF S A G SHCCGS FSLIFLSVLAVIIILYQ
X  .5 -Nucleotidase mouse RIKF S A A SHYQGS FPLVILSLSAVIFVLYQ
CAMPATH-1 antigen TSSP S A S SNISGG IFLFFVANAIIHLFCFS
 .human
 .OX45 antigen mouse DLAR S S G VCWTAT WLVVTTLIIHRILLT
 .VSG MIT 118a T. brucei EKCR N G S FLTSKQ FAFSVVSAAFVALLF
 .VSG MIT 117a T. brucei NACK D S S ILVTKK FALTVVSAAFVALLF
 .PARP T. brucei EPEP G A A TLKSVA LPFAIAAAALVAAF
VSG MITat 1.1000 BC EKCC D G S FLVNKK FALMVYDFVSLLAF
 .T. brucei
 .VSG MITat 1.5b T. brucei EDCR N G S FLTSKQ FALMVSAAFVTLLF
 .CNTN1 human QVKI S G A PTLSPS LLGLLLPAFGILV
 .AChE human GFTH G E A ARRPG LPLPLLLLHQLLLLFLSHLRRL
 .APase human placenta AGTT D A A HPGRS VVPALLPLLAGTLLLLETATAP
 .Folate receptor-a human AAAM S G A GPWAA WPFLLSLALMLLWLLS
 .APase human intestinal ACTT D A A HP VAASLPLLAGTLLLLGASAAP
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 .Table 1 continued
Protein C-Terminal amino acid sequence
Spacer sequence Hydrophobic region
v vq1 vq2
 .APase human liver CAPA S S A GS LAAGPLLVALALYPLSVLF
 .MRC OX-45 antigen rat TLAR S S G VH WIAAWLVVTLSIIPSILLA
 .Gp64 slime mold NNVC S S A TT IAFNAFVVFAIVLSVLLF
 .PsA slime mold STTT G S A ST VVASLSLIIFSMILSLC
 .VCAM1 mouse HLMF A K S FY FICYLCLYLAL
 .w x  .w x  . w x  . w x  . w x  . w x  . w xp137 human 34 , E48 human 35 , CEA human 36 , ThB mouse 37 , Thy-1 rat 38 , Thy-1 human 39 , GAS-1 yeast 40 ,
 . w x  . w x  . w x  . w x  . w xSca-2 mouse 41 , Ly-6C antigen mouse 42 , DAF human 43 , dipeptidase pig 44 , VSG YNat 1.1 T. congolense 45 , PHR1
 . w x  . w x  . w x  . w x  . w x  . w xC. albicans 46 , N-CAM chicken 47 , folate receptor-b human 48 , AP-P pig 49 , GP2 rat 50 , u-PAR human 51 , LFA-3
 . w x  . w x  . w x  . w x  . w x  . w xantigen human 52 , glypican rat 53 , CD59 human 54 , AChE Torpedo 55 , Prion protein hamster 56 , brevican rat 57 ,
 . w x  . w x  . w x  . w xVSG ILTat 1.1 T. brucei 58 , VSG TxTat 1 T. brucei 59 , VSG MIT 221 T. brucei 60 , RT6.2 rat 61 , melanotransferrin
 . w x  . w x X  . w x X  . w x X  . w x Xchicken 62 , DIP human 63 , 5 -nucleotidase rat 64 , 5 -nucleotidase human 65 , 5 -nucleotidase bovine 13 , 5 -nucleotidase
 . w x  . w x  . w x  . w x mouse 66 , CAMPATH-1 antigen human 67 , OX45 antigen mouse 68 , VSG MIT 118a T. brucei 69 , VSG MIT 117a T.
. w x  . w x  . w x  . w x  . w xbrucei 60 , PARP T. brucei 70 , VSG MITat 1.1OOO BC T. brucei 71 , VSG MITat 1.5b T. brucei 72 , CNTN1 human 73 ,
 . w x  . w x  . w x  . w x  .AChE human 74 , APase human placenta 75 , folate receptor-a human 48 , APase human intestine 76 , APase human liver
w x  . w x  . w x  . w x  . w x77 , MRC OX-45 antigen rat 78 , Gp64 slime mold 79 , PsA slime mold 80 , VCAM1 mouse 81 . The sequences are arranged
according to the length of the hydrophilic spacer sequence.
quirement of length and hydrophobicity of the region
w xfor GPI modification 4–6 . The C-terminal amino
acid residue of mature polypeptide covalently bound
to GPI moiety is called the v-site which is followed
by the residues named vq1, vq2 and so on
w xtoward the C-terminus 7 . The transamidase cleaves
the peptide bond of pro-protein at the C-terminal side
of the v-residue, transferring this terminal carboxyl
to the amino group of ethanolamine in GPI. The
C-terminal signal peptide includes a hydrophilic
spacer sequence between the v-site and the hy-
 .drophobic region Table 1 . Although the hydrophilic
spacers are various in length and no obvious consen-
sus is observed among their sequences, it is well
known that the types of amino acid residues at the v-
w xand vq2-sites are restricted 7–10 . Mutational
 . w xanalysis of decay-accelerating factor DAF 11 and
w xartificial spacer of CD46 12 suggested that 9–12
amino acid residues were required as the spacer for
GPI modification. On the other hand, almost a half of
precursor proteins have a hydrophilic spacer se-
quence whose length is less than nine amino acid
residues, as shown in Table 1. Thus the modification
depends not simply on the number of residues in the
sequence.
X  X5 -Nucleotidase 5 -ribonucleotide phosphohydro-
.lase, EC 3.1.3.5 is a GPI-anchored protein which has
been shown to be an ectoenzyme present in a wide
w xvariety of eukaryotic cells 13 . Cloning and sequenc-
ing of the cDNAs coding for the enzyme was previ-
ously reported and the enzyme was expressed as a
GPI-modified form on the cell surface of COS-1
w xtransfected with the cDNA 14 . More than half of the
cDNA product was released from cell surface by
phosphatidylinositol-specific phospholipase C PI-
.PLC , which is common feature of GPI-anchored
w xproteins 15,16 . We have also reported the v-site of
bovine 5X-nucleotidase is Ser 523 by analysis of GPI-
w xlinked C-terminal polypeptide 17 . Therefore, the
enzyme is suitable to investigate the role of spacer
sequence for GPI modification, in that the protein has
a relatively short, 8 residues of spacer sequence. In
this report, we constructed a series of deletion and
elongation mutants of the spacer sequence of 5X-
nucleotidase and examined the effects of the muta-
tions on GPI modification.
2. Materials and methods
2.1. Materials
Plasmid pSVNT is a derivative of pSVL into
which the wild-type cDNA of bovine liver 5X-nucleo-
w xtidase was inserted 14 . M13-mp18 was used as a
vector for mutagenesis. Escherichia coli JM110
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 .dam- and TG1 were used for DNA technology.
Phosphatidylinositol-specific phospholipase C PI-
.PLC was purified from the culture broth of Bacillus
w x Xthuringiensis as described 18 . Adenosine-5 -mono-
 .phosphate AMP was used as a substrate for assay of
the 5X-nucleotidase activity.
2.2. Construction of the deletion mutant genes
A series of deletions were introduced by Eckstein’s
w x oligonucleotide-directed mutagenesis 19–21 Sculp-
tor in vitro mutagenesis system, Amersham Interna-
.tional plc, UK . A 305-bp of HindIII fragment of
5X-nucleotidase cDNA encoding the anchoring signal,
was inserted into the HindIII site of M13-mp18
 .multiple cloning site M13-NTC and used as a tem-
plate for mutagenesis. Mutagenic oligonucleotide was
designed to occupy the complementary sequence of
5X-nucleotidase cDNA. Deletions were introduced to
 523.the coding sequence just after the v-site Ser as
follows: 5X-AAGAAATATCAAAGAAAArACAG-
X CAATGACTTCCTGC-3 complementary to the
. coding sequence of 524A–534L for mutant D 530–
. X531 ; 5 -AAGAAATATCAAAGAAAArATGACT-
X TCCTGCAGAAAA-3 complementary to the coding
.  .sequence of 522L–534L for mutant D 528–531 ;
5X-AAGAAATATCAAAGAAAAr TCCTGCAGAA-
X AACTGGAT-3 complementary to the coding se-
.  .quence of 520I–534L for mutant D 526–531 ; and
5X-AAGAAATATCAAAGAAAAr AGAAAACTG-
X GAT-CCGACC-3 complementary to the coding se-
.  .quence of 518G–534L for mutant D 524–531 . The
fusion point of deletion in each oligonucleotide was
 .denoted by slash. For example, D 530–531 denotes
the deletion mutant lacking the two residues of 530G
and 531S in the hydrophilic spacer. Silent mutation
destroying the SspI site by change of T to C under-
.lined was also introduced to aid for screening of
mutants. To construct the mutant cDNA clones, the
mutated DNA fragments were cut out with EcoO65I
and Bcl I digestion, and exchanged for the corre-
sponding fragment of pSVNT.
2.3. Construction of the elongation mutant genes
Stepwise Ala insertion after Ser531, the end of
spacer sequence of the C-terminal signal, was per-
formed by oligonucleotide-mediated PCR mutagene-
sis using M13-NTC as a template. The mutagenic,
forward and reverse primers designed to insert 2, 4,
6, 7, 8 and 9 Ala residues after Ser 531, respectively,
were as follows: forward 5X-TGTGGAAGTgctgctTT-
TTCTT-TGATA-3X and reverse 5X-TATCAAAGAA-
AAagcagcACTTCCACA-3X primer for mutant
531A2; forward 5X-TGCTGTGGAAGTgctgccgctgcc-
TTTTCTTTGATA-3X and reverse 5X-TATCAAAGA-
AAAggcagcggcagcACTTCCACAGCA-3X primer for
mutant 531A4, forward 5X-TGCTGTGGAAGTgctgc-
cgctgccgctgccTTTTCTTTGATA-3X and 5X-TATCA-
AAGAAAAggcagcggcagcggcagcACTTCCACAG-
CA-3X primer for mutant 531A6, forward 5X-TGTGG-
AAGTgctgctgccgccgctgccgctTTTTCTTTGATAT-
TT-3X and reverse 5X-TATCAAAGAAAAagcggcagc-
ggcggcagcagcACTTCCACAGCA-3X primer for mu-
tant 531A7, forward 5X-TGTGGAAGTgctgctgccgccg-
ctgccgctcgccTTTTCTTTGATATTT-3X and reverse
5X-TATCAAAGAAAAggcagcggcagcggcggcagcagc-
ACTTCCACAGCA-3X primer for mutant 531A8 and
forward 5X-TGTGGAAGTgctgctgccgccgctgccgctgcc-
gctTTTTCTTTGATATTT-3X and reverse 5X-TATC
AAAGAAAAagcggcagcggcagcggcggcagcagcACTT-
CCACcAGCA-3X primer for mutant 531A9. Nu-
cleotide sequence corresponding to Ala insertions
were denoted with small-letters. Silent mutation by
 .change of T to C underlined destroyed the SspI site
in order to aid screening of mutants. 531AX means
 .the mutant gene inserted a definite number sX of
Ala residues after Ser 531. The mutated PCR frag-
ments were exchanged for the corresponding restric-
tion fragment of pSVNT as described above.
2.4. Cell culture and DNA transfection
COS-7 cells, a transformed cell line of African
green monkey kidney cells, were cultured in Dul-
becco’s modified Eagle’s medium Flow Laborato-
. ries supplemented with 10% fetal calf serum BIO-
.Whittaker, Maryland, USA . Transfection of the mu-
tant genes was carried out in the dishes or the flasks
w x using cationic liposome-mediated method 22 Lipo-
.fectAMINE Reagent with serum-free medium
OPTI-MEM I Reduced Serum Medium, Gibco Life
.Technologies, Inc. Grand Island, NY, USA , accord-
ing to the manufacturer’s protocol.
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2.5. Assay of 5X-nucleotidase acti˝ities
The enzyme activity expressed on the cell surface
was measured as follows. The cells in each culture
 .dish 35 mm diameter were washed twice with 1 ml
of ST buffer 0.25 M sucrose and 0.1 mM phenyl-
.methylsulfonyl fluoride in 20 mM Tris-HCl, pH 7.5 .
The cells were incubated with substrate solution 600
.ml containing 5 mM MgCl and 10 mM AMP in 502
mM glycine buffer, pH 8.5, and the hydrolysis of
w xAMP in the supernatant was measured 23 . After
cultivation of transfected cells, media were pooled by
one-tenth of original volume. The cells were washed
twice with ST buffer, harvested, resuspended in the
 .same buffer containing pepstatin 5 mgrml and then
 . Xantipain 5 mgrml , and homogenized. The 5 -
nucleotidase activity in the concentrated media and
the cell homogenate was measured. An enzyme unit
was defined as the amount of the enzyme catalyzing
the hydrolysis of 1 mmol AMP per min at 378C.
2.6. PI-PLC treatment of cells
 6 .Transfected cells 1=10 cells were incubated
with 1 Urml of PI-PLC for 60 min at 378C. After
PI-PLC treatment, the reaction mixture was cen-
trifuged at 19 000=g for 60 min at 48C. Then the
enzyme activities released into the supernatant and
retained on the cells were determined.
2.7. Northern blot analysis of 5X-nucleotidase mRNA
in transfected cells
Total RNA was extracted with guanidium thio-
cyanate followed by centrifugation in lithium chlo-
w x ride and cesium trifluoroacetic acid 24 Quick Prep
.Total RNA extraction Kit, Pharmacia Biotech , elec-
trophoresed and analyzed by RNA blot hybridization
using fluorescein-labeled probe encoding the most of
X  .5 -nucleotidase 1.6-kb BamHI fragment of cDNA .
The hybridized probe was detected by alkaline phos-
phatase-conjugated anti-fluorescein antibody using
w xCDP-Star as a chemiluminescent substrate 25
CDP-Star detection module, Amersham International
.plc, UK , according to the manufacturer’s protocol.
3. Results
As shown in Table 2, the C-terminal signal of
bovine 5X-nucleotidase comprises a hydrophilic spacer
 .sequence 8 amino acid residues and the following
hydrophobic amino acid stretch 17 amino acid
. w xresidues 4 . In order to understand how the hy-
drophilic spacer is responsible for attachment of GPI
 523.to the v-site Ser , a series of mutations within the
spacer were introduced by oligonucleotide-mediated
site-directed mutagenesis. The mutant cDNAs were
constructed by replacement of a 147-bp EcoO65I–
Bcl I fragment encoding from Gly195 to Ile244 of the
wild-type cDNA with a corresponding mutated frag-
 .ment Tables 2 and 4 .
3.1. The effect of deletion of the spacer sequence for
GPI modification
 .Four deletion mutants denoted as D 530–531 ,
 .  .  .D 528–531 , D 526–531 and D 524–531 were de-
void of 2, 4, 6 and 8 residues of the hydrophilic
 .spacer, respectively Table 2 . The gene product of
Table 2
C-Terminal amino acid sequences of the wild-type and deletion mutant cDNAs
cDNA clones v-Residue Spacer sequence Hydrophobic region
523 .Ser
Wild-type - - - - -QFS AGSHCCGS FSLIFLSVLAVIIILYQ
 .D 530–531 - - - - -QFS AGSHCC FSLIFLSVLAVIIILYQ
 .D 528–531 - - - - -QFS AGSH FSLIFLSVLAVIIILYQ
 .D 526–531 - - - - -QFS AG FSLIFLSVLAVIIILYQ
 .D 524–531 - - - - -QFS FSLIFLSVLAVIIILYQ
X  521 548.Amino acid sequences of the C-terminal regions of 5 -nucleotidase Gln –Gln and the deletion mutants are shown in single-letter
 523.codes, and the v-residue Ser is underlined.
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 .mutant D 524–548 which completely lost its down-
stream sequence of the v-site, was secreted into the
 . w xculture medium denoted formerly as 523S 4 .
GPI modification of the protein was evaluated by
measuring the cell surface-bound and the PI-PLC-re-
leased 5X-nucleotidase activities in COS-7 cells trans-
fected with the wild-type and mutants cDNAs. Tran-
sient expression of 5X-nucleotidase on the cell surface
was measured at 48 h after transfection as described
in Section 2: Materials and methods. The expressed
activities associated with intact COS-7 cells were
shown in Table 3. COS-7 cells also expressed an
endogenous 5X-nucleotidase activity as a GPI-
anchored form encoded by the chromosomal gene
w x26 and the activity was taken into account as a basal
control. The surface-associated activity of cells trans-
fected with wild-type plasmid, pSVNT, was elevated
about three times higher than those of controls. Gene
 .product of the mutant D 530–531 was also ex-
pressed on the cell surface, where the enzyme activity
was about one-third that of the wild-type transfectant.
In both cases, significant amounts of the enzyme
 .activities were released by PI-PLC Table 3 , show-
ing that the products were anchored via GPI.
On the other hand, the enzyme activities on the
cells transfected with mutant genes deleted more than
four residues, were not increased significantly, but
comparable, with those of controls. Northern blot
analysis of RNA isolated from the mutant-transfected
cells did not show any difference in the transcrip-
tional level from that of pSVNT-transfectant. There-
fore, such low activities were not due to the low
efficiency in transcription of the mutant cDNAs data
.not shown . The result suggests that the GPI-anchor-
ing of the 5X-nucleotidase needs more than 6 amino
acid residues in the hydrophilic spacer sequence. The
mutant gene products which have less than 4 residues
of spacer sequence, were not able to be modified with
GPI nor to be expressed on the cell surface. There-
fore, we measured the enzyme activities in the cell
homogenates and the culture media to locate the
products by the mutant genes. As shown in Table 3,
 .homogenates of the wild-type- and D 530–531 -
transfected cells contained significant enzyme activi-
ties. Homogenates of transfectants with mutant cD-
NAs deleted more than 4 residues; however, they
exhibited the activities on a level with controls. The
enzyme activities in the culture media of the cells
transfected by wild-type and mutant genes were of
 .the basal level, while the activity of the D 524–548 ,
a secretion mutant, was about 2.5 times higher than
those of controls. The gene products lacking more
than 4 residues of the spacer sequence may be de-
graded intracellularly.
Table 3
5X-Nucleotidase activities in the transfectants of the wild-type and deletion mutants, and their release from the cell surface by PI-PLC
X 6 .Transfected DNA PI-PLC 5 -Nucleotidase activity mUr10 cells
Cell-bound Released Media Cell homogenate
a .pSVNT wild-type y 3.61 0.025 0.509 1.395
aq 2.42 1.13 n.d. n.d.
a .D 530–531 y 1.79 0.04 0.474 0.947
aq 0.80 0.74 n.d. n.d.
a .D 528–531 y 1.15 0.10 0.547 0.628
aq 0.65 0.53 n.d. n.d.
a .D 526–531 y 0.98 0.043 0.519 0.457
aq 0.81 0.54 n.d. n.d.
a .D 524–531 y 1.06 0.030 0.511 0.403
aq 0.96 0.50 n.d. n.d.
 .pSVL vector y 1.19 0.055 0.544 0.522
q 0.77 0.51 n.d. n.d.
a .D 524–548 y n.d. n.d. 1.151 0.412
q n.d. n.d. n.d. n.d.
The transfected cells were incubated with PI-PLC at 378C for 1 h, and 5X-nucleotidase activities released into the reaction supernatant and
retained on the cell surface were determined. Also, 5X-nucleotidase activities in the homogenates and the media were determined. n.d., not
determined.
a Significantly different from the control value at P-0.01.
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Table 4
C-Terminal amino acid sequences of the wild-type and elongation mutant cDNAs
cDNA clones v-Residues Spacer sequence Hydrophobic region
523 .Ser
Wild-type - - - - -QFS AGSHCCGS FSLIFLSVLAVIIILYQ
531A2 - - - - -QFS AGSHCCGSAA FSLIFLSVLAVIIILYQ
531A4 - - - - -QFS AGSHCCGSAAAA FSLIFLSVLAVIIILYQ
531A6 - - - - -QFS AGSHCCGSAAAAAA FSLIFLSVLAVIIILYQ
531A7 - - - - -QFS AGSHCCGSAAAAAAA FSLIFLSVLAVIIILYQ
531A8 - - - - -QFS AGSHCCGSAAAAAAAA FSLIFLSVLAVIIILYQ
531A9 - - - - -QFS AGSHCCGSAAAAAAAAA FSLIFLSVLAVIIILYQ
X  521 548.Amino acid sequences of the C-terminal regions of 5 -nucleotidase Gln –Gln and the elongation mutants are shown in single-letter
 523.codes, and the v-residue Ser is underlined.
3.2. The effect of elongation of the spacer sequence
for GPI modification
Six elongation mutants denoted as 531A2, 531A4,
531A6, 531A7, 531A8 and 531A9, were inserted 2,
4, 6, 7, 8 and 9 residues of Ala after Ser 531, respec-
 .tively Table 4 . Expression levels of 531A2, 531A8
and 531A9 gene products were comparable with that
of wild-type. The cells transfected with 531A4, 531A6
and 531A7 mutant genes also expressed significant
cell-surface enzyme activities, which were partially
suppressed by 30, 50 and 20% that of wild-type,
respectively.
To detect the mutant gene products which failed to
be expressed on the cell surface, the enzyme activi-
ties of the culture media and the cell homogenates
Table 5
5X-Nucleotidase activities in the transfectants of the wild-type and elongation mutants and their release from the cell surface by PI-PLC
X 6 .Transfected DNA PI-PLC 5 -Nucleotidase activity mUr10 cells
Cell-bound Released Media Cell homogenate
a .pSVNT wild-type y 3.735 0.027 0.528 3.833
aq 1.775 2.054 n.d. n.d.
a531A2 y 4.137 0.034 0.548 3.562
aq 1.849 1.893 n.d. n.d.
a531A4 y 2.623 0.055 0.477 2.017
aq 1.207 1.191 n.d. n.d.
a531A6 y 1.887 0.060 0.494 1.793
aq 1.389 0.747 n.d. n.d.
a531A7 y 2.96 0.069 0.394 2.519
aq 1.779 1.427 n.d. n.d.
a531A8 y 4.448 0.056 0.444 3.205
aq 1.536 2.166 n.d. n.d.
a531A9 y 4.087 0.107 0.282 3.079
aq 1.712 1.983 n.d. n.d.
 .pSVL vector y 0.703 0.031 0.455 0.625
q 0.352 0.441 n.d. n.d.
a .D 524–548 y n.d. n.d. 4.370 0.743
q n.d. n.d. n.d. n.d.
The transfected cells were incubated with PI-PLC at 378C for 1 h, and 5X-nucleotidase activities released into the reaction supernatant and
retained on the cell surface were determined. Also, 5X-nucleotidase activities in the homogenates and the media were determined. n.d., not
determined.
a Significantly different from the control value at P-0.01.
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were measured. Significant amounts of the enzyme
activities were observed in the cell homogenate from
the wild-type and all of the elongated mutants Table
.5 . On the contrary, enzyme activities secreted into
the culture media of these cells remained at the basal
level, while the considerable enzyme activity of the
 . D 524–548 was secreted. Due to delay in the step
of concentrating this enzyme, the secreted enzyme
activity of this mutant in Table 3 became much lower
than in Table 5, although the transcription levels of
X .5 -nucleotidase mRNA were almost comparable. Ex-
pression of the gene products which have 12–15
residues of spacer sequence, 531A4-7, were also
suppressed in the cell homogenates. By Northern blot
analysis, however, appreciable difference was not
detected in the transcriptional level among the wild-
type and mutant gene transfectants.
To confirm the GPI anchoring of the enzyme
expressed on the cell surface, transfected cells were
incubated with PI-PLC, and the enzyme activities
released into the supernatant were determined. In
every case, significant amounts of the enzyme activi-
 .ties were released by PI-PLC Table 5 , showing that
the products derived from transfected cDNAs were
anchored via GPI. The results implicated that de-
creased efficiency of GPI modification occurred on
the pro-proteins of mutant 531A4, 531A6 and 531A7,
and the pro-proteins failed to be GPI modified were
degraded immediately.
From the above experiments, the relationship be-
Fig. 1. Relationship between GPI modification and number of
residues of the spacer sequence. The relative activities expressed
on the cell surface of transfectants, were plotted against number
of residues of the spacer sequence. The activity of wild-type
transfectant is indicated as 100%.
tween GPI modification and length of the spacer
 .number of amino acid residues can be summarized
in Fig. 1.
4. Discussion
Amino acid compositions and sequences of C-
terminal signal peptides usually vary with the precur-
sor proteins. Sequences of the C-terminal signal pep-
tides of GPI-anchored proteins were aligned in Table
1, according to the length of hydrophilic spacer se-
quences. Span of the hydrophilic spacer ranges be-
tween 4 and 17 and that of the bovine liver 5X-nucleo-
tidase is 8.
To determine the minimum length of spacer se-
quence more precisely, we trimmed the spacer se-
quence by two amino acid units from the junction of
the spacer with hydrophobic region toward the N-
terminus and examined their expression in COS
 .transfectant Table 2 . By deletion of the last two
residues of the spacer, a significant amount of the
enzyme activity was still expressed, and the activity
was released from the cell surface by PI-PLC Table
.3 . The gene products which have less than 6 residues
of the spacer were not expressed on the cell surface.
Thus it follows that more than 6 residues of hy-
drophilic spacer are required for GPI anchoring of the
5X-nucleotidase. The result is not consistent with those
w x w xof DAF 11 and CD46 12 .
The gene products exhibiting lowered expression
 .  .on the cell surface, D 528–531 , D 526–531 and
 .D 524–531 , were not detected in the cell ho-
mogenates and the culture media. This suggested that
the gene products were not present in the active form
of 5X-nucleotidase. Moran and Caras demonstrated
that incomplete pro-proteins not modified with GPI,
missing to be a substrate of the transamidase, were
accumulated in a sorting compartment between the
w xendoplasmic reticulum and the medial Golgi 27 . In
the mutants of bovine 5X-nucleotidase, the precursor
proteins failed to accept GPI moiety were so unstable
that these proteins may be degraded immediately by
intrinsic proteases.
Since both GPI and the pro-proteins bind to lumi-
nal membrane of the endoplasmic reticulum,
transamidase may also act on the luminal side. The
first three-dimensional structure of transamidase was
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resolved by X-ray crystallography of bacterial peni-
 . w xcillin-binding protein 2x PBP2x 28 . The enzyme
digests a terminal peptide bond of a peptidoglycan to
form an acyl–enzyme intermediate, and then trans-
fers the acyl moiety to an amino group of adjacent
acceptor peptide. In the active-site pocket of the
enzyme, the binding site of the peptidoglycan lies
very close to that of the acceptor peptide. Mode of
reaction of the putative GPI transamidase seems to be
similar to that of PBP2x. The acyl–enzyme interme-
diate of the GPI transamidase with pro-protein was
also reported and the acyl moiety of this intermediate
w xwould be transferred to GPI 29 . Hypothetical mech-
anism of GPI modification was schematically repre-
sented in Fig. 2. The pro-protein, a substrate of GPI
transamidase, must bind to the active-site pocket of
the enzyme which is proximate to the binding pocket
 .of GPI Fig. 2 . The spacial arrangement of the
terminal amino group of GPI would be restricted,
because the diradyl moiety of GPI is buried in the
luminal membrane. Spacial relationship of the v-site
with the hydrophobic region of pro-protein may be
conserved among various pro-proteins. Binding face
of the pro-protein to the enzyme is assumed to be the
v- and vq2-residues because of their restriction for
GPI modification. Therefore, the spacer sequence
Fig. 2. Hypothetical mechanism of GPI modification. A: the pro-protein and the GPI, substrates of GPI transamidase, bind to form an
E–S complex with the transamidase on the luminal side of the endoplasmic reticulum. Binding pockets of these substrates are closely
located on the active-site cleft of the transamidase. B: the reaction mechanism of GPI transfer to the pro-protein was schematically
 .represented. After formation of E–S complex, nucleophilic group of the active-site residue showed in bold capital, N attacks the
carbonyl carbon of v-residue, forming an acyl–enzyme intermediate. Then, the acyl moiety of the intermediate is transferred to the
 .terminal amino group of GPI NH C H O- , and GPI anchoring is completed.2 2 4
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may play a role in arranging the v- and vq2-
residues for correct binding to the active site of the
GPI transamidase. By deletion of the spacer se-
quence, the gene products anchored by GPI were
reduced. On the contrary, transfectant of mutant
531A2 which had 10 residues of spacer sequence
expressed the comparable amount of 5X-nucleotidase
activity with that of wild-type having 8 residues of
spacer sequence. Thus, the spacer length of 8–10
residues is suitable for GPI modification, as shown in
Fig. 1. The number of residues of the wild-type
spacer sequence, 8, may suffice requirement to keep
the most efficient GPI modification.
Although the transfectants of 531A4, 531A6 and
531A7 were partially suppressed in the 5X-nucleo-
tidase activity, those of 531A8 and 531A9 having
more than 16 residues of spacer sequences expressed
cell-surface activity comparable with that of wild-
type. The modification with GPI may occur at the
 . 523alternative residue s located downstream of Ser ,
resulting in optimization of the length of spacer
sequences. For example, if Ser 531 of 531A8 mutant
became a v-residue, the length of spacer sequence
would be 8 and the v- and vq2-residues would be
Ser and Ala, respectively, being compatible to ‘the v
and vq2 rule’. The alteration of GPI-modified site
 .was reported in folate receptor FR by Yan and
w xRatnam 30 . In the FR mutant having altered v-re-
sidue, the enzyme activity was expressed only 20%
that activity of wild-type, due to insufficient length of
spacer sequence. The amino acid sequence of the
spacer of bovine 5X-nucleotidase is AGSHCCGS, and
combinations of His and Cys as well as Cys and Ser
w xare not suitable for the v- and vq2-residue 9 . In
this sequence, GPI modification of the gene products
of 531A4 and 531A6 were partially suppressed since
His and Cys were not acceptable for a v-residue to
regulate the length of spacer sequence. Thus, the
v-residue of these mutants may be Ser523 and sup-
pression of GPI modification was caused by the
mutations. On the contrary, partial restoration of the
suppression observed in 531A7 probably resulted
from partial alteration of the v-residue.
By deletion of more than 4 residues of the spacer,
complete suppression of the GPI modification was
observed. On the other hand, elongation of the spacer
up to 6 residues resulted in partial reduction of
 .anchor modification Fig. 1 , suggesting that elonga-
tion of the spacer is more permissible than deletion.
In all of these elongation mutants, the spacer se-
quences enabled the v-residue to enter into the ac-
tive-site pocket because of its flexibility. Since the
natural pro-proteins whose spacer sequences range
from 4 to 17 residues are considered to be catalyzed
by the similar transamidase, it will explain that each
spacer makes unique conformation and thereby leads
the v-residue to the binding pocket of GPI transami-
dase. Nevertheless, the length of the spacer sequence
may influence efficiency of GPI modification by its
positive or negative control.
w x w xRecently, Gaa1p 31 and Gpi8p 32 , a part of the
putative GPI transamidase of yeast, were reported,
w xand GPI-deficient mutant cell lines were found 33 .
Gpi8p shows significant homology to a novel family
of vacuolar plant endopeptidases, one of which is
supposed to catalyze a transamidation step in the
maturation of concanavalin A. Formation of the
acyl–enzyme intermediate was also monitored by
w xusing nucleophilic reagents 29 . Reconstitution of
reaction system of GPI transamidation using combi-
nation of these mutants and site-directed mutagenesis
of the C-terminal signal sequence, would promote to
clarify the molecular mechanism of GPI modifica-
tion.
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